دورية أكاديمية
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy.
| العنوان: | Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy. |
|---|---|
| المؤلفون: | Coorens THH; Broad Institute of MIT and Harvard, Cambridge, MA, USA. tcoorens@broadinstitute.org., Collord G; Great Ormond Street Hospital for Children, London, UK., Treger TD; Wellcome Sanger Institute, Hinxton, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Department of Paediatrics, University of Cambridge, Cambridge, UK., Adams S; Great Ormond Street Hospital for Children, London, UK., Mitchell E; Wellcome Sanger Institute, Hinxton, UK.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Newman B; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Getz G; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Godfrey AL; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Bartram J; Great Ormond Street Hospital for Children, London, UK., Behjati S; Wellcome Sanger Institute, Hinxton, UK. sb31@sanger.ac.uk.; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. sb31@sanger.ac.uk.; Department of Paediatrics, University of Cambridge, Cambridge, UK. sb31@sanger.ac.uk. |
| المصدر: | Nature cancer [Nat Cancer] 2023 Aug; Vol. 4 (8), pp. 1095-1101. Date of Electronic Publication: 2023 Jul 20. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Nature Publishing Group, [2020]- |
| مواضيع طبية MeSH: | Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics , Antibodies, Bispecific*/therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics, Child ; Female ; Humans ; T-Lymphocytes |
| مستخلص: | Children with acute lymphoblastic leukemia (ALL) undergoing anti-CD19 therapy occasionally develop acute myeloid leukemia (AML). The clonal origin of such lineage-switch leukemias 1-4 remains unresolved. Here, we reconstructed the phylogeny of multiple leukemias in a girl who, following multiply relapsed ALL, received anti-CD19 cellular and antibody treatment and subsequently developed AML. Whole genome sequencing unambiguously revealed the AML derived from the initial ALL, with distinct driver mutations that were detectable before emergence. Extensive prior diversification and subsequent clonal selection underpins this fatal lineage switch. Genomic monitoring of primary leukemias and recurrences may predict therapy resistance, especially regarding anti-CD19 treatment. (© 2023. The Author(s).) |
| References: | Nat Genet. 2014 Feb;46(2):116-25. (PMID: 24413735) Nat Commun. 2021 Feb 8;12(1):865. (PMID: 33558546) Nat Immunol. 2007 May;8(5):463-70. (PMID: 17440452) Nat Med. 2022 Apr;28(4):743-751. (PMID: 35288693) Nat Methods. 2015 May;12(5):380-1. (PMID: 25924071) Nature. 2018 Oct;562(7727):373-379. (PMID: 30209392) Nature. 2022 Aug;608(7924):724-732. (PMID: 35948631) Nature. 2021 Apr;592(7852):80-85. (PMID: 33692543) Bioinformatics. 2009 Nov 1;25(21):2865-71. (PMID: 19561018) Cancer Sci. 2022 Jul;113(7):2472-2476. (PMID: 35467057) N Engl J Med. 2020 Nov 5;383(19):1860-1865. (PMID: 33211929) Bioinformatics. 2009 Jul 15;25(14):1754-60. (PMID: 19451168) Nat Commun. 2021 Feb 12;12(1):985. (PMID: 33579957) Curr Protoc Bioinformatics. 2016 Dec 8;56:15.10.1-15.10.18. (PMID: 27930805) Science. 2019 Dec 6;366(6470):1247-1251. (PMID: 31806814) Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5. (PMID: 20837533) Blood. 2021 May 27;137(21):2992-2997. (PMID: 33598691) Nature. 2016 May 02;534(7605):47-54. (PMID: 27135926) Blood Cancer J. 2017 Sep 15;7(9):e607. (PMID: 29016570) Nature. 2015 Feb 26;518(7540):552-555. (PMID: 25487151) Blood Cancer Discov. 2020 Jul;1(1):96-111. (PMID: 32793890) Cold Spring Harb Perspect Med. 2017 Aug 1;7(8):. (PMID: 28270531) Leuk Lymphoma. 2017 May;58(5):1162-1171. (PMID: 27756164) Blood. 2022 Oct 27;140(17):1875-1890. (PMID: 35839448) Blood. 2020 Jan 2;135(1):41-55. (PMID: 31697823) Cell. 2012 May 25;149(5):994-1007. (PMID: 22608083) Blood. 2016 May 19;127(20):2406-10. (PMID: 26907630) Nature. 2012 Jan 11;481(7382):506-10. (PMID: 22237025) Nature. 2021 Sep;597(7876):387-392. (PMID: 34433963) |
| معلومات مُعتمدة: | United Kingdom WT_ Wellcome Trust |
| المشرفين على المادة: | 4FR53SIF3A (blinatumomab) 0 (Antibodies, Bispecific) |
| تواريخ الأحداث: | Date Created: 20230720 Date Completed: 20230825 Latest Revision: 20230922 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10447231 |
| DOI: | 10.1038/s43018-023-00604-0 |
| PMID: | 37474833 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. | تدمد: | 2662-1347 |
|---|---|
| DOI: | 10.1038/s43018-023-00604-0 |